Equity Overview
Price & Market Data
Price: $33.10
Daily Change: +$33.10 / 100.0%
Daily Range: $33.10 - $33.10
Market Cap: $1,443,058,944
Daily Volume: 4,113,516
About Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
A complete financial picture of Hemab Therapeutics Holdings, Inc. Common Stock (COAG). Current price: 33.10, daily change: +$33.10 / 100.0%. Market cap: 1,443,058,944. Performance over 1-month and 6-month periods.
Details
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.